Brief: Moberg Pharma Reports Topline Data In The North American Phase 3 Study And Will Regain Rights To MOB-015 In EU

Moberg Pharma AB (publ)

10/12/2024 19:32

Dec 10 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA REPORTS TOPLINE DATA IN THE NORTH AMERICAN
PHASE 3
STUDY AND WILL REGAIN RIGHTS TO MOB-015 IN EU
    * MOBERG PHARMA AB (PUBL) - MOB-015 DID NOT MEET PRIMARY
ENDPOINT
IN PHASE 3
    * MOBERG PHARMA - BAYER AND CO EXPRESSED MUTUAL INTENT TO
TERMINATE LICENSE AGREEMENT WHEREBY MOBERG PHARMA REGAINS FULL
RIGHTS FOR MOB-015 IN EU

Source text:  ID:nWkrbtY39K 
Further company coverage:  MBPH.ST 

 ((Reuters.Briefs@thomsonreuters.com;))